YEARMED 2025- Session 2: Endocrine Nephrology updates

Описание: Welcome to YEARMED Episode 2 - Endocrine Nephrology Updates 2024-2025! 🎯
Join Dr. Om Lakhani and Dr. Ipsita Ghosh as they discuss four practice-changing updates in endocrine nephrology and diabetic kidney disease.
📋 Topics Covered:
1. Primary Aldosteronism - New Endocrine Society Guidelines

Why PA is more common than we think (5-15% of hypertensive patients)
Simplified screening process - no need to stop most antihypertensive medications
Myths debunked: Not all patients need surgery or have hypokalemia
When to screen: Young hypertensives, resistant hypertension, adrenal incidentalomas
Precision medicine approach with MR antagonists

2. CONFIDENCE Trial - Dual Therapy in CKD

Starting SGLT2 inhibitors and Finerenone together safely
52% reduction in urine albumin-creatinine ratio with combination therapy
Managing hyperkalemia and EGFR dip concerns
Four pillars of diabetic kidney disease management

3. Aldosterone Synthetase Inhibitors - Future of Hypertension

Baxdrostat and Lorundostat trial results
How they differ from MR antagonists
Benefits in resistant hypertension and CKD
Lower side effect profile

4. GLP-1 Receptor Agonists in Obesity Nephropathy

SELECT trial sub-analysis insights
22-23% reduction in kidney composite outcomes
Obesity-related kidney disease recognition
Role beyond diabetes management

👨‍⚕️ Faculty:
Dr. Ipsita Ghosh - MD, DM Endocrinology, Consultant Endocrinologist & Faculty at RKMSVP VIMS Narayan Superspeciality Hospital, Kolkata
🎓 Key Takeaways:
✅ Screen young hypertensive patients for primary aldosteronism
✅ Consider dual SGLT2i + Finerenone therapy early in CKD
✅ Monitor potassium and creatinine at 1-2 weeks after starting combination therapy
✅ GLP-1RAs beneficial beyond diabetes in obesity-related kidney disease
✅ Knowledge dissemination crucial for endocrine conditions
⏰ Timestamps:
00:00 Introduction
14:00 Primary Aldosteronism - Overview & Importance
36:00 New Screening Guidelines & Myths
54:00 CONFIDENCE Trial Discussion
1:06:00 Aldosterone Synthetase Inhibitors
1:19:00 GLP-1RAs in Obesity Nephropathy
1:22:00 Q&A Session
📚 Resources:
Full papers, presentations, and summaries available on technocrinology.com
Link will be emailed to participants
💊 This session is supported by Lupin AjaDuo with complete editorial freedom.
🔔 Subscribe to Endocrinology India for more updates!
💬 Drop your questions in the comments below
#Endocrinology #PrimaryAldosteronism #DiabeticKidneyDisease #SGLT2Inhibitors #Finerenone #GLP1RA #MedicalEducation #CME #Nephrology #HypertensionManagement #ObesityNephropathy #EndocrineNephrology.